bluebird bio, Inc. (NASDAQ:BLUE) Short Interest Down 8.5% in November

bluebird bio, Inc. (NASDAQ:BLUE) saw a large drop in short interest in the month of November. As of November 15th, there was short interest totalling 43,640,000 shares, a drop of 8.5% from the October 31st total of 47,710,000 shares. Based on an average trading volume of 6,510,000 shares, the short-interest ratio is presently 6.7 days.

bluebird bio Stock Down 10.2 %

NASDAQ BLUE traded down $0.04 on Tuesday, reaching $0.37. 4,649,656 shares of the company were exchanged, compared to its average volume of 7,340,205. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.33 and a current ratio of 0.51. The business’s fifty day moving average price is $0.45 and its 200 day moving average price is $0.73. bluebird bio has a fifty-two week low of $0.29 and a fifty-two week high of $5.53.

bluebird bio (NASDAQ:BLUE) last issued its earnings results on Friday, September 13th. The biotechnology company reported ($0.36) EPS for the quarter. The firm had revenue of $18.57 million for the quarter. bluebird bio had a negative return on equity of 322.46% and a negative net margin of 565.74%. Equities analysts expect that bluebird bio will post -1.35 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently commented on BLUE shares. Cantor Fitzgerald restated a “neutral” rating on shares of bluebird bio in a research report on Monday, September 16th. Royal Bank of Canada reiterated a “sector perform” rating and set a $4.00 price objective on shares of bluebird bio in a research report on Friday, November 15th. StockNews.com began coverage on bluebird bio in a research note on Tuesday, November 26th. They set a “sell” rating for the company. Wells Fargo & Company reduced their price objective on bluebird bio from $3.00 to $2.00 and set an “equal weight” rating on the stock in a research note on Wednesday, September 25th. Finally, Bank of America lowered shares of bluebird bio from a “buy” rating to a “neutral” rating and cut their target price for the company from $3.00 to $0.50 in a report on Friday, November 15th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, bluebird bio currently has a consensus rating of “Hold” and a consensus target price of $3.03.

Hedge Funds Weigh In On bluebird bio

Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in shares of bluebird bio by 19.6% in the first quarter. Vanguard Group Inc. now owns 10,498,460 shares of the biotechnology company’s stock valued at $13,438,000 after purchasing an additional 1,723,081 shares during the period. Price T Rowe Associates Inc. MD grew its stake in shares of bluebird bio by 113.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 54,714 shares of the biotechnology company’s stock worth $71,000 after acquiring an additional 29,113 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of bluebird bio by 19.4% in the second quarter. Bank of New York Mellon Corp now owns 685,757 shares of the biotechnology company’s stock valued at $675,000 after acquiring an additional 111,574 shares in the last quarter. Rhumbline Advisers boosted its holdings in bluebird bio by 25.4% in the second quarter. Rhumbline Advisers now owns 292,436 shares of the biotechnology company’s stock valued at $288,000 after purchasing an additional 59,219 shares during the period. Finally, Allegheny Financial Group LTD acquired a new position in bluebird bio during the 2nd quarter worth $25,000. Institutional investors and hedge funds own 87.43% of the company’s stock.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.